Efficacy and Safety of Amlodipine with Torsemide in CKD with Hypertension in a Tertiary Care Hospital: A Prospective Observational Study

Document Type : Original Article

Authors

1 Department of Pharmacology, Calcutta National Medical College, Kolkata, India

2 Department of Pharmacology, Prafulla Chandra Sen Government Medical College, Arambagh, Hooghly India.

10.30476/tips.2025.106656.1293

Abstract

Managing hypertension in chronic kidney disease (CKD) patients remains challenging, especially in resource-constrained settings like India where comorbidities are prevalent. Combining amlodipine, a calcium channel blocker, with torsemide, a long-acting loop diuretic, may enhance blood pressure control while preserving renal function. To assess the efficacy and safety of amlodipine–torsemide combination therapy in controlling blood pressure and maintaining renal function among hypertensive CKD patients.  This prospective, observational study was conducted over 12 months at a tertiary care hospital in Kolkata. A total of 104 adult CKD patients with uncontrolled hypertension were enrolled and initiated on a fixed or free combination of amlodipine and torsemide. Follow-up evaluations were performed at 3, 6, and 12 months. The primary outcome was change in systolic (SBP) and diastolic blood pressure (DBP). Secondary outcomes included renal function (serum creatinine, eGFR), electrolyte levels, and incidence of adverse drug reactions (ADRs). Significant reductions in blood pressure were observed over 12 months (SBP: 156.7±12.3 to 134.5±9.1 mmHg; DBP: 92.6±7.4 to 80.2±6.8 mmHg; p<0.001). Blood pressure control was achieved in over 67% of patients. Renal parameters remained stable, with no significant change in eGFR or serum creatinine. Electrolyte imbalances were minimal and ADRs were infrequent. Non-diabetic patients showed comparatively better renal outcomes. Amlodipine–torsemide combination therapy appears to be effective and well-tolerated for hypertension management in CKD patients, offering a viable alternative when RAAS inhibitors are unsuitable. Further head-to head randomized clinical trials are recommended.

Highlights

Avishek Mazumder (Google Scholar)

Sk Sabir Rahaman (Google Scholar)

Keywords

References

1.    Bargman JM, Skorecki K. Chronic kidney disease. In: Loscalzo J, Longo DL, Fauci AS, Hauser SL, Jameson JL, editors. Harrison’s Principles of Internal Medicine. 21st ed. New York: McGraw Hill; 2022. p. 2350.
2.    Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int. 2019 Nov;96(5):1048-1050. doi: 10.1016/j.kint.2019.07.012. Epub 2019 Sep 30. PMID: 31582227.
3.    GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015 Jan 10;385(9963):117-71. doi: 10.1016/S0140-6736(14)61682-2. Epub 2014 Dec 18. PMID: 25530442; PMCID: PMC4340604.
4.    Rhee CM, Kovesdy CP. Epidemiology: Spotlight on CKD deaths—increasing mortality worldwide. Nat Rev Nephrol. 2015 Apr;11(4):199-200. doi: 10.1038/nrneph.2015.25. Epub 2015 Mar 3. PMID: 25734769; PMCID: PMC4379111.
5.    Panesar S, Chaturvedi S, Saini NK, Avasthi R, Singh A. Prevalence and predictors of hypertension among residents aged 20-59 years of a slum-resettlement colony in Delhi, India. WHO South East Asia J Public Health. 2013 Apr-Jun;2(2):83-87. doi: 10.4103/2224-3151.122937. PMID: 28612764.
6.    Bhadoria AS, Kasar PK, Toppo NA, Bhadoria P, Pradhan S, Kabirpanthi V. Prevalence of hypertension and associated cardiovascular risk factors in Central India. J Family Community Med. 2014 Jan;21(1):29-38. doi: 10.4103/2230-8229.128775. PMID: 24695988; PMCID: PMC3966094.
7.    Rajapurkar MM, John GT, Kirpalani AL, Abraham G, Agarwal SK, Almeida AF, et al. What do we know about chronic kidney disease in India: first report of the Indian CKD registry. BMC Nephrol. 2012 Mar 6;13:10. doi: 10.1186/1471-2369-13-10. PMID: 22390203; PMCID: PMC3350459.
8.    Varma PP. Prevalence of chronic kidney disease in India - Where are we heading? Indian J Nephrol. 2015 May-Jun;25(3):133-5. PMID: 26060360; PMCID: PMC4446915.
9.    Matovinović MS. 1. Pathophysiology and Classification of Kidney Diseases. EJIFCC. 2009 Apr 20;20(1):2-11. PMID: 27683321; PMCID: PMC4975264.
10.    Chang AR, Loser M, Malhotra R, Appel LJ. Blood pressure goals in patients with CKD: a review of evidence and guidelines. Clin J Am Soc Nephrol. 2019;14(1):161–169.
11.    Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024 Apr;105(4S):S117–S314. doi: 10.1016/j.kint.2023.10.018.
12.    Meyboom RH, Hekster YA, Egberts AC, Gribnau FW, Edwards IR. Causal or casual? The role of causality assessment in pharmacovigilance. Drug Saf. 1997;17:374–389.
13.    Uppsala Monitoring Centre. Safety Monitoring of Medicinal Products: Guidelines for Setting Up and Running a Pharmacovigilance Centre. Uppsala, Sweden: UMC; 2000.
14.    Eschenhagen T. Treatment of ischemic heart disease. In: Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw Hill; 2022. p. 613.
15.    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288(23):2998–3007. doi:10.1001/jama.288.23.2998.
16.    Abraham G, Almeida A, Gaurav K, Khan MY, Patted UR, Kumaresan M. Reno protective role of amlodipine in patients with hypertensive chronic kidney disease. World J Nephrol. 2022 May 25;11(3):86-95. doi:10.5527/wjn.v11.i3.86.
17.    Jo W, Koh ES, Chung S. Therapeutic roles of thiazides and loop diuretics in blood pressure control and renal protection against chronic kidney disease. Clin Hypertens. 2023;29(1):14. doi:10.1186/s40885-023-00238-5.
18.    Georgianos PI, Agarwal R. Hypertension in chronic kidney disease—treatment standard 2023. Nephrol Dial Transplant. 2023 Nov 30;38(12):2694-2703. doi:10.1093/ndt/gfad118.
35.    Yahfoufi N, Alsadi N, Jambi M, Matar C. The Immunomodulatory and Anti-Inflammatory Role of Polyphenols. Nutrients. 2018 Nov 2;10(11):1618. doi: 10.3390/nu10111618. PMID: 30400131; PMCID: PMC6266803.
36.    Schaller M, Gonser L, Belge K, Braunsdorf C, Nordin R, Scheu A, Borelli C. Dual anti-inflammatory and anti-parasitic action of topical ivermectin 1% in papulopustular rosacea. J Eur Acad Dermatol Venereol. 2017 Nov;31(11):1907-1911. doi: 10.1111/jdv.14437. Epub 2017 Aug 29. PMID: 28653460.
37.    Chen TH, Chang PC, Chang MC, Lin YF, Lee HM. Chloroquine induces the expression of inducible nitric oxide synthase in C6 glioma cells. Pharmacol Res. 2005 Apr;51(4):329-336. doi: 10.1016/j.phrs.2004.10.004
38.    Abo El-Noor MM, Elgazzar FM, Alshenawy HA. Role of inducible nitric oxide synthase and interleukin-6 expression in estimation of skin burn age and vitality. J Forensic Leg Med. 2017 Nov;52:148-153. doi: 10.1016/j.jflm.2017.09.001. Epub 2017 Sep 12. PMID: 28926822.
39.    Mansourpour H, Ziari K, Motamedi SK, Poor AH. Therapeutic effects of iNOS inhibition against vitiligo in an animal model. Eur J Transl Myol. 2019 Aug 6;29(3):8383. doi: 10.4081/ejtm.2019.8383. 
40.    Younas, Khan A, Shehzad O, Seo EK, Onder A, Khan S. Anti-allergic activities of Umbelliferone against histamine- and Picryl chloride-induced ear edema by targeting Nrf2/iNOS signaling in mice. BMC Complement Med Ther. 2021 Aug 27;21(1):215. doi: 10.1186/s12906-021-03384-1. PMID: 34452623; PMCID: PMC8394045.
Trends in Pharmaceutical Sciences and Technologies
Volume 11, Issue 3
September 2025
Pages 263-270

Files

Share

How to cite

Statistics